January 1, 1997Thrombosis and Haemostasis
Pharmacokinetics of Recombinant Hirudin in Hemodialyzed End-stage Renal Failure Patients
Why the study?
What are the pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients compared to healthy controls?
Population
20 hemodialysis-treated end-stage renal failure patients and 5 healthy controls
Comparison
Recombinant hirudin administered as a bolus at… vs Healthy controls receiving the same dose
Design
Cohort
Follow-up
6 dialysis sessions
Authors
Discussion
Loading...
Member takes
Implication
Requires caution with hirudin dosing in hemodialysis patients; leaves open optimal regimens for end-stage renal disease.
Structured PICO
What are the pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients compared to healthy controls?
P
Population
20 hemodialysis-treated end-stage renal failure patients and 5 healthy controls
I
Intervention
Recombinant hirudin (HBW 023) administered as a bolus at the start of a single dialysis (0.02 to 0.08 mg/kg)
C
Comparator
Healthy controls receiving the same dose
O
Outcome
Pharmacokinetic parameters of recombinant hirudin (half-life, area under the curve, distribution volume)surrogate
Hirudin removal is markedly depressed in hemodialyzed end-stage renal failure patients, resulting in a significantly prolonged half-life and increased area under the curve.
Cite This Study
Vanholder et al. (1997) studied this question.